ProxyMiner / Company

BIO-TECHNE CorpTECH

Latest proxy: 2025 · view on SEC ↗ · CIK 0000842023

↓ Export PDF

← All companies

CEO total pay

$8,151,181

Kim Kelderman · 2025

Say on pay

5.4%

Latest disclosed shareholder vote

CEO pay ratio

CD&A

88.9 to 1

Median employee: $91,707

Compensation committee

CD&A

Compensation Committee

Per the latest proxy

Filings indexed: 2 · 2025 · 2024

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

Executive	Role	TotalYoY	Pay mix	Salary	Stock	Cash incentive	Other
Kim Kelderman2025 compensation	President and CEO	$8,151,181↑ 19%	88% at-risk	$936,000	$3,929,942	$1,318,917	$33,473
James Hippel2025 compensation	Executive Vice President and CFO	$7,027,382↑ 35%	89% at-risk	$723,000	$4,453,020	$926,163	$17,926
William Geist2025 compensation	President, Protein Sciences	$3,139,299↓ 14%	81% at-risk	$573,200	$1,206,585	$748,026	$18,040
Matthew McManus2025 compensation	President, Diagnostics and Spatial Biology	$2,846,619↑ 43%	79% at-risk	$572,000	$1,213,200	$444,787	$19,937
Shane Bohnen2025 compensation	Senior Vice President and General Counsel	$1,980,732↑ 36%	77% at-risk	$431,000	$767,575	$386,478	$18,183

Pay mix: base cash incentive equity other

Add to peer comparison →Year-over-year diff →

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

In this Compensation Discussion and Analysis (“CD&A”), we provide an overview of our executive compensation philosophy and objectives and describe the material components of our executive compensation program. Please also review the tables that immediately follow this section, which provide more information, including historical compensation information. As of June 30, 2025, the following officers were our Named Executive Officers (or NEOs): KIM KELDERMAN President and Chief Executive Officer JAMES HIPPEL Executive Vice President – Finance and Chief Financial Officer WILLIAM GEIST President – Protein Sciences MATTHEW MCMANUS President – Diagnostics and Spatial Biology SHANE BOHNEN Senior Vice President – General Counsel and Corporate Secretary Executive Summary In fiscal 2025 we successfully navigated strong industry headwinds, including considerable inflationary pressure and market volatility, as well as a rapidly evolving macro environment—all while continuing to execute on our long-term growth strategy. Our focus and commercial execution remained strong and we delivered financial performance that was among the best of our life science technology peers. Our strategy for deliverin…

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

hedging
No hedging/no pledging
“No hedging/no pledging”
pledging
No hedging/no pledging
“No hedging/no pledging”
clawback
present
“recoupment policy, which is applicable to current and former executive officers, requires recoupment of incentive-based compensation where a restatement indicates that an overpayment occurred.”
stock ownership guidelines
present
“ownership requirements”
change in control
Change of Control Events
“Change of Control Events”
compensation consultant
independent
“independent compensation consultant furthers the objectives of the Company’s compensation program.”
compensation committee
Compensation Committee
“Compensation Committee Report on Executive Compensation”

Performance markers

Metric facts

revenue
$384.1
“Impact of foreign currency(1) (4.0) Revenue from acquisitions(2) (24.8) Other revenue(3) (4.2) Organic revenue $1,186.6 (1) For the long-term incentive compensation plans, foreign currency is locked at the rate utilized …”
operating income
$380
“of assets held-for-sale 80,503 Impact of business held-for-sale(1) 479 Adjusted operating income $383,589 Impact from foreign currency $(3,124) Adjusted operating income for fiscal year 2025 earned incentives* $380,465 P…”
annual incentive payout
90%
“For fiscal year 2025, the annual bonus plan for most of our NEOs was again based on consolidated adjusted EBITA results and consolidated organic revenue results for the Company.”
performance equity mix
40%
“In addition, 50% of our CEO’s target long-term incentive equity grant was in the form of three-year performance-based RSUs.”
time equity mix
50%
“25% time-based stock options, 25% time-based RSUs, and 50% three-year performance-vested RSUs.”
say on pay
5.4%
“Say on Pay proposal in 2024. This support reflects the value of our ongoing dialogue with shareholders and the enhancements we’ve made to our compensation program in response to their input. We thank our shareholders for…”
ceo pay ratio
88.9 to 1
“of Item 402(c)(2)(x) of Regulation S-K, which resulted in annual total compensation of $91,707. For the year ended June 30, 2025, the total compensation for our CEO, Mr. Kelderman, was $8,151,181 as reported in the Summa…”
median employee compensation
$91,707
“total compensation of all of our employees (other than our CEO), commonly referred to as the “pay ratio” disclosure. As required by the SEC rules, we updated our analysis in fiscal year 2025 to identify our median employ…”

Ask

Anything about BIO-TECHNE Corp’s 2025 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…